Gelonghui April 19 丨 Yifan Pharmaceutical (002019bonusdeuceswild.SZ) announced its 2023 annual report, with operating income of 40% during the reporting periodbonusdeuceswild.68 billion yuan, a year-on-year increase of 6.03%bonusdeuceswild; attributable to shareholders of listed companiesbonusdeuceswildNet profit of-551 million yuan, a year-on-year profit turned to loss; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses-533 million yuan; basic earnings per share-0.45 yuan.
转载声明：本站发布文章及版权归原作者所有，转载本站文章请注明文章来源！